Data to be presented today at 2019 Muscular Dystrophy Association Clinical and Scientific Conference Phase 2/3 clinical trial for suvodirsen in DMD expected to initiate in July 2019 Interim efficacy data from ongoing open-label extension study expected in H2 2019...
Helps sponsors apply medical imaging in trials to advance development of NAFLD/NASH therapeutics. Bioclinica®, a leading provider of science and technology expertise to assist the life science industry in advancing the development of medical therapies, announced today...
— United BioPharma’s novel antibody suppresses HIV without eliciting resistance United BioPharma (UBP) today announced that its monoclonal antibody product, UB-421, is able to suppress HIV for at least four months in patients who previously paused their...
– Oral integrin antagonist inhibits multiple processes of pathologic fibrosis – Indalo to present at NASH Summit in Boston, MA, on April 24th Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patients...
TrialAssure® – a leading, global software company focused on developing clinical trial transparency tools – announced today the launch of TrialAssure REGISTRY 2.5, the latest iteration of TrialAssure’s premiere clinical trial registration and disclosure...
The GAIN Trial will assess whether a new investigational medicine targeting P. gingivalis bacteria can slow or halt progression of Alzheimer’s disease Researchers seek more than 500 participants in the United States and Europe; visit www.GAINtrial.com for information...
Email
Text